Overview

* Achieve submitted NDA for cytisinicline to FDA, marking a major milestone

* Co raised $49.3 mln in public offering to advance cytisinicline

* Q2 loss per share misses estimates; net loss and loss from operations beat estimates, per LSEG data

Outlook

* Achieve expects funding to support operations into H2 2026

Result Drivers

* NDA SUBMISSION - Achieve submitted NDA for cytisinicline to FDA, marking a major milestone

* PARTNERSHIP - Co partnered with Omnicom to streamline cytisinicline launch, aiming to reduce costs and optimize performance

* PUBLIC OFFERING - Achieve raised $49.3 mln in public offering to support cytisinicline advancement

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS Miss -$0.37 -$0.36

(5

Analysts

)

Q2 Net Beat -$12.72 -$12.90

Income mln mln (5

Analysts

)

Q2 Beat -$12.56 -$13.10

Income mln mln (5

From Analysts

Operatio )

ns

Q2 $12.56

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Achieve Life Sciences Inc ( ACHV ) is $14.00, about 81.1% above its August 6 closing price of $2.64

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)